Published in J Clin Invest on June 18, 2012
Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev (2013) 1.26
Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology (2013) 0.96
Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase. Cereb Cortex (2012) 0.95
Deletion of Adenosine A2A Receptors From Astrocytes Disrupts Glutamate Homeostasis Leading to Psychomotor and Cognitive Impairment: Relevance to Schizophrenia. Biol Psychiatry (2015) 0.84
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry (2014) 0.81
Homeostatic control of brain function - new approaches to understand epileptogenesis. Front Cell Neurosci (2013) 0.81
Comorbidities in Neurology: Is adenosine the common link? Neuropharmacology (2015) 0.80
Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophr Res (2014) 0.80
Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning. Behav Brain Res (2012) 0.80
Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics (2015) 0.79
Purinergic signaling and energy homeostasis in psychiatric disorders. Curr Mol Med (2015) 0.79
Adenosine and autism: a spectrum of opportunities. Neuropharmacology (2012) 0.79
Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". Purinergic Signal (2013) 0.78
Adenosinergic signaling in epilepsy. Neuropharmacology (2015) 0.78
Dysregulation of brain adenosine is detrimental to the expression of conditioned freezing but not general Pavlovian learning. Pharmacol Biochem Behav (2013) 0.77
Transcriptome outlier analysis implicates schizophrenia susceptibility genes and enriches putatively functional rare genetic variants. Hum Mol Genet (2015) 0.77
A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res (2013) 0.76
Sleep-Wake Regulation and Its Impact on Working Memory Performance: The Role of Adenosine. Biology (Basel) (2016) 0.75
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
Presynaptic inhibition of elicited neurotransmitter release. Trends Neurosci (1997) 2.82
Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) (2008) 2.64
Modeling madness in mice: one piece at a time. Neuron (2006) 2.60
Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci (2004) 2.25
Presynaptic inhibition in the hippocampus. Trends Neurosci (1993) 2.20
Adenosine and brain function. Int Rev Neurobiol (2005) 1.97
Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest (2008) 1.86
A ketogenic diet suppresses seizures in mice through adenosine A₁ receptors. J Clin Invest (2011) 1.79
The ketogenic diet: one decade later. Pediatrics (2007) 1.54
Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res (2001) 1.54
Adenosine receptors and the central nervous system. Handb Exp Pharmacol (2009) 1.53
Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther (2000) 1.51
Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain (2005) 1.51
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) (2003) 1.49
Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav (2007) 1.48
Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A (2001) 1.47
Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions. EMBO J (2011) 1.40
Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci (2010) 1.40
Adenosine signaling and function in glial cells. Cell Death Differ (2009) 1.39
Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets (2006) 1.34
Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab (2006) 1.30
NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol (2004) 1.29
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci (2008) 1.27
Adenosine dysfunction in astrogliosis: cause for seizure generation? Neuron Glia Biol (2007) 1.23
Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. Neurodegener Dis (2007) 1.22
Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) (1997) 1.19
Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res (2009) 1.17
Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. Nutr Metab (Lond) (2009) 1.13
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull (2005) 1.08
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther (2000) 1.06
Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem Pharmacol (2009) 1.03
Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience (2000) 1.02
Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry (2006) 1.02
Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy. Neuropharmacology (2011) 1.02
Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Mem (2011) 1.01
Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci (2007) 1.00
Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology (2003) 1.00
Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience (1994) 0.97
Adenosine kinase determines the degree of brain injury after ischemic stroke in mice. J Cereb Blood Flow Metab (2011) 0.95
The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behav Brain Res (2005) 0.92
Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav Brain Res (2003) 0.91
Receptor-receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Transm (Vienna) (2006) 0.90
Preferential enhancement of working memory in mice lacking adenosine A(2A) receptors. Brain Res (2009) 0.90
Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophr Res (2000) 0.87
Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice. Psychopharmacology (Berl) (2009) 0.87
Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.87
What knock-out animals tell us about the effects of caffeine. J Alzheimers Dis (2010) 0.86
Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Curr Opin Pharmacol (2009) 0.86
Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol (2001) 0.84
Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients. Rev Bras Psiquiatr (2010) 0.84
Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem (2011) 0.83
Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice. Neuropsychopharmacology (2004) 0.82
Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res (1998) 0.81
Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment. Neurosci Lett (2007) 0.77
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Detection of functional DNA motifs via statistical over-representation. Nucleic Acids Res (2004) 6.31
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci (2010) 3.38
The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci (2006) 3.03
Abnormal differentiation of newborn granule cells in age-related working memory impairments. Neurobiol Aging (2008) 2.38
Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci (2005) 2.34
Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci (2004) 2.25
Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest (2003) 2.22
Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol (2005) 2.19
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
Adenosine and brain function. Int Rev Neurobiol (2005) 1.97
A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol (2006) 1.94
Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med (2004) 1.93
Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun (2007) 1.86
Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest (2008) 1.86
Magnetic resonance observation of cartilage repair tissue (MOCART) for the evaluation of autologous chondrocyte transplantation: determination of interobserver variability and correlation to clinical outcome after 2 years. Eur J Radiol (2005) 1.80
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol (2006) 1.79
A ketogenic diet suppresses seizures in mice through adenosine A₁ receptors. J Clin Invest (2011) 1.79
Psychosis pathways converge via D2high dopamine receptors. Synapse (2006) 1.78
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev (2005) 1.70
A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J Immunol (2012) 1.67
CREB-mediated Bcl-2 protein expression after ischemic preconditioning. J Cereb Blood Flow Metab (2005) 1.60
Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials (2008) 1.57
Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav Neurosci (2007) 1.56
Adenosine A(2A) receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation. Kidney Int (2011) 1.55
Double dissociation of the effects of selective nucleus accumbens core and shell lesions on impulsive-choice behaviour and salience learning in rats. Eur J Neurosci (2005) 1.54
Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol (2002) 1.53
Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem (2005) 1.53
Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain (2005) 1.51
Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol (2002) 1.50
Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain (2007) 1.50
A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull (2008) 1.49
Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol (2004) 1.45
The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist (2007) 1.42
Dissociation of function between the dorsal and the ventral hippocampus in spatial learning abilities of the rat: a within-subject, within-task comparison of reference and working spatial memory. Eur J Neurosci (2004) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum (2003) 1.41
Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol (2006) 1.40
Inhibition of Adenosine Kinase Attenuates Acute Lung Injury. Crit Care Med (2016) 1.39
Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia (2003) 1.38
Cartilage repair: generations of autologous chondrocyte transplantation. Eur J Radiol (2005) 1.37
Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci (2011) 1.35
Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy. J Clin Invest (2004) 1.34
Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. J Neurosci (2002) 1.31
Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab (2006) 1.30
Genetic deletion of A2A adenosine receptors in the striatum selectively impairs habit formation. J Neurosci (2009) 1.29
Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol (2007) 1.27
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov (2013) 1.27
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci (2008) 1.27
Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun (2005) 1.27
Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci (2005) 1.24
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci (2006) 1.23
Adenosine dysfunction in astrogliosis: cause for seizure generation? Neuron Glia Biol (2007) 1.23
Sleep regulation in adenosine A2A receptor-deficient mice. Neurology (2003) 1.22
Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. J Cereb Blood Flow Metab (2007) 1.18
Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol (2009) 1.18
Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure activity but not activity-dependent adenosine release in the hippocampus. Neuropharmacology (2008) 1.18
Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology (2007) 1.18
Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.14
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice. Behav Brain Res (2007) 1.13
Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des (2008) 1.13
Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol (2005) 1.11
A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology (2005) 1.10
Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab (2011) 1.10
Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem (2005) 1.10
Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest (2013) 1.09
Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. Neurosci Lett (2005) 1.09
The impact of voluntary exercise on mental health in rodents: a neuroplasticity perspective. Behav Brain Res (2008) 1.09
Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. J Control Release (2010) 1.09
Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci (2010) 1.08
The International Society for Developmental Psychobiology annual meeting symposium: Impact of early life experiences on brain and behavioral development. Dev Psychobiol (2006) 1.08
Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol (2009) 1.08
Human-specific histone methylation signatures at transcription start sites in prefrontal neurons. PLoS Biol (2012) 1.08
A novel mouse model for sudden unexpected death in epilepsy (SUDEP): role of impaired adenosine clearance. Epilepsia (2009) 1.07
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull (2008) 1.07
Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death. Eur J Neurosci (2003) 1.07
Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology (2002) 1.05
How do the basal ganglia regulate sleep-wake behavior? Trends Neurosci (2012) 1.05
Influence of differential housing on emotional behaviour and neurotrophin levels in mice. Behav Brain Res (2006) 1.05
Characterization of neuronal death induced by focally evoked limbic seizures in the C57BL/6 mouse. J Neurosci Res (2002) 1.05
Disruption of hippocampus-regulated behavioural and cognitive processes by heterozygous constitutive deletion of SynGAP. Eur J Neurosci (2010) 1.05
Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants. J Cereb Blood Flow Metab (2006) 1.04
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology (2003) 1.04
Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res (2006) 1.03
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci (2006) 1.03
Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci (2006) 1.03
Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett (2004) 1.02
Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging (2007) 1.02
Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy. Neuropharmacology (2011) 1.02
Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice. Am J Physiol Lung Cell Mol Physiol (2007) 1.02
Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn Mem (2011) 1.01